ERBB2 and breast carcinoma: Furthermore, Glaser et al. were able to extend the SiFA methodology to affibody labeling in 2013, generating an [18F]-SiFA-labeled human epidermal growth factor receptor (HER2)-targeted affibody, ZHER2:2891, for the imaging of HER2-positive breast cancer [99].